RP-1664

Revisión del cliente

Based on 1 Customer Validation

RP-1664 is a selective and orally active PLK4 inhibitor with an IC50 of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of PLK4 and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research[1][2].

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 98.77%
  • No. CAS: 2980682-00-4
  • Fòrmula: C23H24F2N8O2S
  • Peso molecular:514.55
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs

Ver todos los productos específicos de isoformas Polo-like Kinase (PLK)

More
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00